Puma Biotechnology Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Puma Biotech (PBYI) Tops Q3 EPS by 59c, Revenues Miss
November 6, 2019 6:03 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q3 EPS of ($0.12), $0.59 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $60.4 million.
In the third quarter of 2019 we were pleased to report that our supplemental New Drug Application for neratinib for the treatment of third-line HER2-positive metastatic breast cancer was accepted by the... More



